CN Patent

CN107148419A — Zeste增强子同源物2抑制剂

Assigned to GlaxoSmithKline Intellectual Property No 2 Ltd · Expires 2017-09-08 · 9y expired

What this patent protects

本发明涉及新的式(I)化合物，其为Zeste增强子同源物2(EZH2)的抑制剂，含有它们的药物组合物，它们的制备方法以及它们在治疗癌症的疗法中的用途。

USPTO Abstract

本发明涉及新的式(I)化合物，其为Zeste增强子同源物2(EZH2)的抑制剂，含有它们的药物组合物，它们的制备方法以及它们在治疗癌症的疗法中的用途。

Drugs covered by this patent

tazemetostat-hydrobromide (TAZEMETOSTAT HYDROBROMIDE)

Patent Metadata

Patent number: CN107148419A
Jurisdiction: CN
Classification: —
Expires: 2017-09-08
Drug substance claim: No
Drug product claim: No
Assignee: GlaxoSmithKline Intellectual Property No 2 Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.